Matthew Daniels
About Matthew Daniels
Matthew Daniels is an Associate Director at Accent Therapeutics, Inc., where he has worked since 2022. He holds a BS and MS in Chemistry from Northeastern University and has extensive experience in the biotechnology sector, including roles at Goldfinch Bio and Novartis Institutes for BioMedical Research.
Current Role at Accent Therapeutics
Matthew Daniels serves as the Associate Director at Accent Therapeutics, Inc. He has held this position since 2022. In this role, he contributes to the strategic direction and scientific initiatives of the organization. His experience in the field of chemistry and drug development supports the company's mission to advance innovative therapies.
Previous Experience at Accent Therapeutics
Prior to his current role, Matthew Daniels worked at Accent Therapeutics, Inc. as a Principal Scientist from 2020 to 2022. In this capacity, he focused on research and development projects that align with the company's therapeutic goals. His tenure at Accent Therapeutics reflects his commitment to advancing scientific knowledge in the pharmaceutical sector.
Experience at Goldfinch Bio
Matthew Daniels has significant experience at Goldfinch Bio, where he worked as a Senior Scientist in Chemistry from 2018 to 2020. Before that, he served as a Scientist in Chemistry from 2017 to 2018. His roles involved conducting research and developing chemical solutions to support the company's objectives in drug discovery.
Educational Background in Chemistry
Matthew Daniels studied at Northeastern University, where he earned both a Bachelor of Science and a Master of Science in Chemistry. His undergraduate studies spanned from 2003 to 2007, providing him with a solid foundation in chemical principles and research methodologies that he has applied throughout his career.
Experience at Novartis Institutes for BioMedical Research
Matthew Daniels worked at Novartis Institutes for BioMedical Research from 2013 to 2017 as a Scientist I. He also completed a Chemogenetics Co-op at the same institution in 2005. His time at Novartis involved engaging in various research projects that contributed to advancements in biomedical research.